Distribution of markers in each of the 4 EMC92-ISS–based risk groups
| . | EMC92 . | ISS . | del17p . | del13q . | 1q gain . | HR.FISH.A . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMC92-ISS . | HR . | n . | 1 . | 2 . | 3 . | n . | Positive . | n . | Positive . | n . | Positive . | n . | HR . | n . |
| Low | 0% | 365 | 100% | 0% | 0% | 365 | 8% | 39 | 44% | 39 | 34% | 154 | 75% | 76 |
| Intermediate-low | 0% | 231 | 0% | 100% | 0% | 231 | 5% | 60 | 37% | 60 | 34% | 92 | 44% | 70 |
| Intermediate-high | 0% | 211 | 0% | 0% | 100% | 211 | 8% | 66 | 44% | 66 | 41% | 101 | 55% | 84 |
| High | 100% | 166 | 30% | 32% | 39% | 166 | 16% | 38 | 74% | 39 | 76% | 90 | 93% | 76 |
| . | EMC92 . | ISS . | del17p . | del13q . | 1q gain . | HR.FISH.A . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EMC92-ISS . | HR . | n . | 1 . | 2 . | 3 . | n . | Positive . | n . | Positive . | n . | Positive . | n . | HR . | n . |
| Low | 0% | 365 | 100% | 0% | 0% | 365 | 8% | 39 | 44% | 39 | 34% | 154 | 75% | 76 |
| Intermediate-low | 0% | 231 | 0% | 100% | 0% | 231 | 5% | 60 | 37% | 60 | 34% | 92 | 44% | 70 |
| Intermediate-high | 0% | 211 | 0% | 0% | 100% | 211 | 8% | 66 | 44% | 66 | 41% | 101 | 55% | 84 |
| High | 100% | 166 | 30% | 32% | 39% | 166 | 16% | 38 | 74% | 39 | 76% | 90 | 93% | 76 |
The numbers in the data for which the EMC92-ISS risk classification could be determined. For the classifications based on del13q, 1q gain, and HR.FISH.A, a clear correlation was found to the EMC92-ISS classifications. For instance, 93% of EMC92-ISS high-risk patients are positive for HR.FISH.A compared with 44 to 55% of the intermediate group and 75% of the low group.
HR, the percentage of patients indicated as high-risk according to the specified marker; n, number of patients in the EMC92-ISS–based risk group for which the specified marker was available; positive, the percentage of patients positive for the specified marker.